Astaxanthin / Apoptosis Cancer Research Results

ASTX, Astaxanthin: Click to Expand ⟱
Features:

Astaxanthin — a lipophilic xanthophyll carotenoid antioxidant (often sourced from Haematococcus pluvialis microalgae and also present in salmon/crustaceans) used as a nutraceutical with prominent redox and inflammation-modulating biology. It is formally classified as a small-molecule dietary carotenoid (natural product / nutraceutical). Common abbreviations include ASTX and AXT. In oncology-context literature it is primarily discussed as a chemopreventive/cytoprotective redox modulator with context-dependent direct antitumor effects, and with theoretical concern for antagonizing ROS-mediated chemo/radiation mechanisms in some settings.
The European Commission considers natural astaxanthin as a food dye

Primary mechanisms (ranked):

  1. NRF2 pathway activation with downstream antioxidant/phase-II enzyme program (context-dependent; often cytoprotective)
  2. Suppression of inflammatory signaling including NF-κB axis with downstream COX-2/iNOS and cytokine modulation
  3. Growth/survival signaling modulation (context-dependent), commonly reported on PI3K–AKT, ERK/MAPK, STAT3
  4. Mitochondria-linked apoptosis induction and cell-cycle perturbation in select tumor models (dose/model-dependent)
  5. Anti-migration/anti-EMT phenotype (e.g., MMPs, cadherin switch; model-dependent)
  6. Ferroptosis/redox-lethal interactions reported in limited models (model-dependent)

Bioavailability / PK relevance: Poor aqueous solubility and variable oral absorption (fat/formulation-dependent). Plasma exposure is typically low with standard oral supplements; engineered formulations (micellar/nanoemulsion) can increase Cmax and shorten Tmax. Reported terminal half-life in healthy volunteers is on the order of ~1–2 days in at least one human PK study.

In-vitro vs systemic exposure relevance: Many mechanistic cancer studies use micromolar astaxanthin concentrations that can exceed typical human plasma levels after supplementation; therefore, mechanistic claims are frequently concentration- and formulation-limited for systemic antitumor translation.

Clinical evidence status: Predominantly preclinical (cell/animal) for direct anticancer claims. Human evidence is stronger for oxidative stress/inflammation biomarker modulation than for anticancer efficacy endpoints; not an approved anticancer drug. Practical oncology use is mainly adjunctive/chemopreventive framing, with caution discussed around concurrent ROS-dependent chemo/radiation.

Astaxanthin is a xanthophyll carotenoid with exceptionally strong antioxidant capacity. In cancer biology, it shows context-dependent effects—largely chemopreventive and cytoprotective, with limited evidence as a direct antineoplastic agent.
Astaxanthin significantly promotes the proliferation of Akkermansia, a microorganism with enhanced anti-tumor immune effects.
Anti-inflammatory signaling, Astaxanthin can inhibit: NF-κB, COX-2, iNOS
Astaxanthin commonly Activates NRF2: Upregulates antioxidant enzymes (GSH, SOD, CAT, GPX)
-Protective in normal tissues
-Potentially tumor-protective in established cancers

Often discouraged during active chemotherapy or radiation
It may:
-Protect tumor cells from ROS-mediated killing
-Reduce lipid peroxidation-based therapies
This concern is similar to:
-Vitamin E
-Trolox
-High-dose carotenoids

Astaxanthin is less likely to be pro-oxidant than lycopene or β-carotene.
Some reports indicate a pro-oxidant effect, but at concentrations that are not achievable for in vito.

Astaxanthin — mechanistic pathway map (cancer-context)

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 NRF2 antioxidant response ↑ NRF2 (context-dependent) → ↓ ROS injury; may blunt ROS-lethal therapies ↑ NRF2 → ↑ GSH/SOD/CAT/GPx; cytoprotection R/G Redox buffering and stress tolerance Often positioned as protective; in established tumors this can be tumor-supportive depending on therapy and redox state.
2 NF-κB inflammatory signaling ↓ NF-κB → ↓ pro-survival inflammation (model-dependent) ↓ inflammatory cytokine signaling R/G Anti-inflammatory microenvironment shift Commonly linked to ↓ COX-2/iNOS and reduced inflammatory tone.
3 PI3K–AKT survival signaling ↓ PI3K/AKT (model-dependent) → ↑ apoptosis, ↓ proliferation ↔ / mild cytoprotective bias (context-dependent) R/G Survival pathway suppression in select tumors Directionality is model- and dose-dependent; some datasets show mixed AKT effects.
4 ERK/MAPK signaling ↓ ERK/MAPK (model-dependent) → ↓ proliferation/EMT ↔ / ↓ stress-activated signaling (context-dependent) R/G Anti-growth signaling modulation Often reported alongside PI3K/AKT changes; may converge on apoptosis/cell-cycle effects.
5 STAT3 axis ↓ STAT3 → ↓ proliferation, ↓ immune-evasion programs (model-dependent) ↔ G Reduced oncogenic transcription signaling Reported in prostate and other models; typically framed as anti-tumor signaling.
6 Mitochondria-mediated apoptosis ↑ intrinsic apoptosis (BAX↑, Bcl-2↓, caspases↑; model-dependent) ↓ stress-induced apoptosis (cytoprotection) R Cell death modulation Key “anti-tumor” readout in many studies; may require higher concentrations than typical systemic exposure.
7 Cell cycle control ↑ p21/p27 and/or arrest signatures (model-dependent) ↔ G Proliferation braking Often co-occurs with apoptosis; direction varies with cell line and dosing.
8 EMT and matrix remodeling ↓ EMT; ↓ MMPs; ↑ E-cadherin (model-dependent) ↔ G Anti-migration / anti-metastatic phenotype Reported via miRNA and cadherin/MMP changes in some colon/breast models.
9 Angiogenesis signaling ↓ VEGF/EGFR signaling (limited, model-dependent) ↔ G Reduced pro-angiogenic drive Less consistently central than NRF2/NF-κB/PI3K–AKT in the literature.
10 Ferroptosis and lipid peroxidation balance ↔ / ↑ ferroptosis (limited models) but also ↓ lipid peroxidation (context-dependent) ↓ lipid peroxidation injury R Redox-lethal interaction or protection (context-dependent) Net effect depends strongly on baseline oxidative state and whether therapy relies on lipid peroxidation.
11 Clinical Translation Constraint Low/variable oral exposure; many in-vitro effects are high-concentration. Antioxidant/NRF2 biology raises a plausible antagonism risk for ROS-dependent chemo/radiation (context-dependent). Formulation and dosing strategy strongly influence exposure. — Translational ceiling Best-supported human domain is oxidative stress/inflammation biomarkers rather than anticancer efficacy endpoints.

TSF legend: P: 0–30 min    R: 30 min–3 hr    G: >3 hr
Apoptosis, Apoptosis: Click to Expand ⟱
Source:
Type: type of cell death
Situation in which a cell actively pursues a course toward death upon receiving certain stimuli.
Cancer is one of the scenarios where too little apoptosis occurs, resulting in malignant cells that will not die.
Scientific Papers found: Click to Expand⟱
4821- ASTX,    Astaxanthin Reduces Stemness Markers in BT20 and T47D Breast Cancer Stem Cells by Inhibiting Expression of Pontin and Mutant p53
- in-vitro, BC, SkBr3 - in-vitro, BC, BT20 - in-vitro, BC, T47D
Apoptosis↑, CSCs↓, OCT4↓, Nanog↓, TumCP↓,
4823- ASTX,    Astaxanthin increases radiosensitivity in esophageal squamous cell carcinoma through inducing apoptosis and G2/M arrest
- in-vitro, ESCC, NA
RadioS↑, Apoptosis↑, TumCCA↑, Bcl-2↓, CycB/CCNB1↓, CDC2↓, BAX↑,
5419- ASTX,    Astaxanthin and other Nutrients from Haematococcus pluvialis—Multifunctional Applications
- Review, Nor, NA
*antiOx↑, *Inflam↓, *AntiDiabetic↓, AntiCan↑, *lipid-P↓, TumCP↓, Apoptosis↑, TumCCA↑, *SOD↑, *PGE2↓, *NO↓, *IL8↓, *IFN-γ↓, *cardioP↑, *NF-kB↓, *TNF-α↓, *BioAv↑,
4820- ASTX,    Astaxanthin suppresses the malignant behaviors of nasopharyngeal carcinoma cells by blocking PI3K/AKT and NF-κB pathways via miR-29a-3p
- in-vitro, NPC, NA
TumCP↓, TumCI↓, Apoptosis↑, TumCCA↑, cycD1/CCND1↓, Bcl-2↓, P21↑, BAX↑, PI3K↓, Akt↓, NF-kB↓, miR-29b↑,
4804- ASTX,    Astaxanthin in cancer therapy and prevention (Review)
- Review, Var, NA - Review, AD, NA
*antiOx↑, *Inflam↓, ChemoSen⇅, chemoP↑, BioAv↑, TumCP↑, ROS⇅, Apoptosis↑, PI3K↑, Akt↑, GSK‐3β↑, NRF2↑, AntiCan↑, *neuroP↑, eff↑, AntiTum↑,
4819- ASTX,    Astaxanthin Induces Apoptosis in MCF-7 Cells through a p53-Dependent Pathway
- in-vitro, BC, MCF-7
antiOx↑, AntiTum↑, TumCD↑, P53↑, P21↑, Apoptosis↑, Dose↝, Casp3↑,
4814- ASTX,    Chemopreventive and therapeutic efficacy of astaxanthin against cancer: A comprehensive review
- Review, Var, NA
Apoptosis↑, EMT↓, AntiCan↑, *cardioP↑, *neuroP↑, TumCG↓, *antiOx↑, *Bacteria↓, *Imm↑, *hepatoP↑, *AntiDiabetic↑, ROS↓, *chemoPv↑,
4812- ASTX,    Astaxanthin suppresses the metastasis of colon cancer by inhibiting the MYC-mediated downregulation of microRNA-29a-3p and microRNA-200a
- in-vitro, CRC, HCT116
miR-29b↑, miR-200b↑, MMP2↓, Zeb1↓, EMT↓, Apoptosis↑, ERK↓, MAPK↓, PI3K↓, Akt↓, MMPs↓, TumMeta↓,
4808- ASTX,    Anti-Tumor Effects of Astaxanthin by Inhibition of the Expression of STAT3 in Prostate Cancer
- in-vitro, Pca, DU145 - in-vivo, NA, NA
TumCP↓, STAT3↓, Apoptosis↑, TumCMig↓, TumCI↓,
4807- ASTX,    An overview of the anticancer activity of astaxanthin and the associated cellular and molecular mechanisms
- Review, Var, NA
*antiOx↑, *neuroP↑, AntiCan↑, TumCG↓, TumCD↑, TumCMig↓, ChemoSen↑, chemoP↑, *BioAv↓, TumCP↓, TumCCA↑, Apoptosis↑, BioAv↑,
4806- ASTX,    Astaxanthin's Impact on Colorectal Cancer: Examining Apoptosis, Antioxidant Enzymes, and Gene Expression
- in-vitro, CRC, HCT116
BAX↑, Casp3↑, Apoptosis↑, Bcl-2↓, MDA↓, ROS↓, SOD↑, Catalase↑, GPx↑, antiOx↑, TumCG↓, TumCP↓,
4805- ASTX,    Astaxanthin promotes apoptosis by suppressing growth signaling pathways in HT-29 colorectal cancer cells
- in-vitro, Colon, HT29
TumCP↓, Casp3↑, EGFR↓, HER2/EBBR2↓, ERK↓, Apoptosis↑,

Showing Research Papers: 1 to 12 of 12

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 12

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 2,   Catalase↑, 1,   GPx↑, 1,   MDA↓, 1,   NRF2↑, 1,   ROS↓, 2,   ROS⇅, 1,   SOD↑, 1,  

Mitochondria & Bioenergetics ⓘ

CDC2↓, 1,  

Cell Death ⓘ

Akt↓, 2,   Akt↑, 1,   Apoptosis↑, 12,   BAX↑, 3,   Bcl-2↓, 3,   Casp3↑, 3,   MAPK↓, 1,   TumCD↑, 2,  

Kinase & Signal Transduction ⓘ

HER2/EBBR2↓, 1,  

DNA Damage & Repair ⓘ

P53↑, 1,  

Cell Cycle & Senescence ⓘ

CycB/CCNB1↓, 1,   cycD1/CCND1↓, 1,   P21↑, 2,   TumCCA↑, 4,  

Proliferation, Differentiation & Cell State ⓘ

CSCs↓, 1,   EMT↓, 2,   ERK↓, 2,   GSK‐3β↑, 1,   Nanog↓, 1,   OCT4↓, 1,   PI3K↓, 2,   PI3K↑, 1,   STAT3↓, 1,   TumCG↓, 3,  

Migration ⓘ

miR-200b↑, 1,   miR-29b↑, 2,   MMP2↓, 1,   MMPs↓, 1,   TumCI↓, 2,   TumCMig↓, 2,   TumCP↓, 7,   TumCP↑, 1,   TumMeta↓, 1,   Zeb1↓, 1,  

Angiogenesis & Vasculature ⓘ

EGFR↓, 1,  

Immune & Inflammatory Signaling ⓘ

NF-kB↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 2,   ChemoSen↑, 1,   ChemoSen⇅, 1,   Dose↝, 1,   eff↑, 1,   RadioS↑, 1,  

Clinical Biomarkers ⓘ

EGFR↓, 1,   HER2/EBBR2↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 4,   AntiTum↑, 2,   chemoP↑, 2,  
Total Targets: 56

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 4,   lipid-P↓, 1,   SOD↑, 1,  

Angiogenesis & Vasculature ⓘ

NO↓, 1,  

Immune & Inflammatory Signaling ⓘ

IFN-γ↓, 1,   IL8↓, 1,   Imm↑, 1,   Inflam↓, 2,   NF-kB↓, 1,   PGE2↓, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   BioAv↑, 1,  

Functional Outcomes ⓘ

AntiDiabetic↓, 1,   AntiDiabetic↑, 1,   cardioP↑, 2,   chemoPv↑, 1,   hepatoP↑, 1,   neuroP↑, 3,  

Infection & Microbiome ⓘ

Bacteria↓, 1,  
Total Targets: 20

Scientific Paper Hit Count for: Apoptosis, Apoptosis
12 Astaxanthin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:382  Target#:14  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page